



HEALEY ALS Platform Trial



Investigational Products Tested in the Trial



Pridopidine
January 21, 2021



Merit Cudkowicz, MD
Principal Investigator



Healey Center

Sean M. Healey & AMG Center
for ALS at Mass General

Sabrina Paganoni, MD, PhD
Co-Principal Investigator



THE ARTHUR M. BLANK
FAMILY FOUNDATION



Accelerating ALS Therapy Development

Traditional



	Intervention
Disease	Treatment A



Platform




	Intervention			
Disease	Treatment A	Treatment B	Treatment C	Treatment D

Perpetual Adaptive Trial

Randomization Ratio 3:1; Shared Placebo

Open Label Extension offered



Regimen Leads

Jeremy Shefner, MD, PhD
Barrow Neurological Institute, Phoenix, AZ
Regimen Lead



Björn Oskarsson, MD, FAAN
Mayo Clinic, Jacksonville, FL
Regimen co-Lead





Pridopidine for ALS:

Healey Platform Trial
Regimen D



FAQs

- 1 What is pridopidine?
- 2 What is the Sigma-1 Receptor (S1R)?
- 3 Why is the S1R a good target for an ALS therapy?
- 4 Why test pridopidine for ALS?
- 5 Was pridopidine tested in people before?
- 6 How do you know pridopidine gets into the brain and spinal cord in people?
- 7 Is there any evidence that pridopidine slows progression of other diseases?
- 8 How do you know pridopidine is safe?

1

What is pridopidine?

What is pridopidine?


- A small molecule investigational drug in clinical trials for **ALS** and **Huntington disease (HD)**
- Pridopidine is **administered orally** twice a day (BID), in the morning and in the afternoon
- Pridopidine binds and specifically activates a receptor called the **Sigma-1 receptor**
- **Pridopidine is safe and tolerable**. The dose tested for ALS has a side effect profile like that of placebo in clinical studies in Huntington disease.
- In patients with Huntington disease, **pridopidine is the first drug to show maintenance** of total functional capacity (TFC).
- This effect is durable **up to 5 years** (longest time that has been analyzed to date)
- **TFC is the most accepted scale used** to assess HD patient function and disease progression, and is accepted by the regulatory agencies as a single primary endpoint in clinical trials

2

What is the Sigma-1 Receptor (S1R)?

What is the Sigma-1 receptor (S1R)?

- A protein highly expressed in the brain and spinal cord, particularly in motor neurons
- Plays an important role in the cell's response to stress
- Activation of the S1R has neuroprotective effects:
 - Reduces degeneration and death of neurons
 - Enhances neuronal health and function by increasing energy production and clearance of toxic proteins
 - Increases neuronal connectivity
 - Reduces cellular stress and neuroinflammation



3


Why is the S1R a good target for ALS?

High distribution of S1R in brain areas implicated in ALS


S1R is highly expressed in the brain stem, spinal cord and cortex

High expression of S1R mRNA:

Brainstem and Spinal Cord



Cortex



low  high

Human validation: Genetic mutations in S1R cause ALS

The S1R gene




Complete Loss of function mutations located near the ligand binding site → cause Juvenile ALS

Partial loss of function mutations → cause late-onset ALS

- ER signal motif
- Trans-membrane motif
- Ligand binding motif

Lack of S1R exacerbates disease progression in ALS mice

- Mice with a mutation in the SOD1 gene are a common model used in ALS research
- Removing the S1R gene (S1R^{-/-}) from SOD1 mice accelerates disease progression and decreases survival (in purple)




4

Why test pridopidine for ALS?

Pridopidine activation of the S1R positively influences **multiple pathways** that lead to neuroprotection

S1R activation ↑ **Neuroprotection**




1. Christ et al, Cells. 2019; 2. Tesei et al, Frontiers in Pharmacology. 2018; 3. Hayashi and Su, Cell. 2007; 4. Tsai et al, PNAS. 2009; 5. Hayashi et al, Trends in Cell Biol. 2009; 6. Fujimoto et al, Synapse. 2012; 7. Xu et al, Psychopharmacology. 2014; 7. Kourrich et al, Trends Neurosci. 2012; 8. Ryskamp et al, Front. Neurosci. 2019; 9. Pal et al, Eur J Pharmacol. 2012. 10. Ryskamp et al, NBD. 2017 11.Allen Brain Atlas Data Portal

Pridopidine rescues the neuron-muscle connection in ALS mice


- The neuron-muscular junction (NMJ) is the connection between neuron and muscle
- In ALS mice, the NMJ is disrupted (left)
- Pridopidine rescues this connection (neuron + muscle labeling shows as yellow on the right)

Ionescu et al., Cell Death & Disease 2019


Untreated



+ pridopidine



- Muscle
- Neuron
- NMJ Connection (neuron + muscle)




SOD1 G93A ALS model mice

Pridopidine rescues the neuron-muscle function in ALS cells

- Healthy cells show high muscle contractility (blue, left bar)
- Disruption of the neuron-muscle connection in ALS cells → less muscle contractility (purple, middle bar)
- Pridopidine rescues muscle contractility in ALS (purple, right bar)

Ionescu et al., Cell Death & Disease 2019



5

**Was pridopidine tested
in people before?**

Yes.



Pridopidine has been tested in

> 1300  people

the majority of them Huntington
disease patients



To date

22 Clinical studies
have been performed

for pridopidine, with some
of these running for **5+**
years


6

**How do you know pridopidine
gets into the brain and
spinal cord in people?**

Pridopidine gets into the **brain and spinal cord** and **binds the S1R** at the clinical dose


18F-Fluspidine (labeled drug that binds the S1R) S1R occupancy

Without pridopidine



- We can radioactively label **fluspidine**, a known **S1R** binding drug
- We can then view this labeled drug in the brain

With pridopidine



- Pridopidine prevents fluspidine binding to the **S1R** after an oral dose
- Prevention of labeled fluspidine binding in the brain by pridopidine shows its **strong and selective binding** to the S1R


Grachev et al; NEMJJ 2020

7

**Is there any evidence that
pridopidine slows progression
of other diseases?**

Pridopidine is the **only drug** that has shown a **beneficial effect** on **Total Functional Capacity (TFC)** in HD

- TFC is a scale that assesses disease progression and functionality in HD patients
- In HD patients pridopidine maintained functional capacity compared with placebo



HD shares many similarities with ALS:

HD patients and families highlight decreased **functional capacity** as a **major burden on daily life**



Participants strongly emphasized the **burden of HD** left them **unable to perform many, if not all daily activities**



The **13-point TFC scale** captures changes in HD patients' capacity to continue working, driving, performing household activities, **eating (due to fear of choking), feeding themselves, dressing themselves, walking**, getting out of bed, and completing simple tasks



Participants noted that they have become increasingly or fully **dependent on others** for care, as HD symptoms worsened



Years of research, in both the lab and the clinic show beneficial effects of pridopidine for treating neurodegenerative disease.

**This effect is significant
and durable.**



8

**How do you know
pridopidine is safe?**

Pridopidine has an extensive safety and tolerability profile

Extensive clinical experience

> 1300
subjects

in total of ~1300
patient years

The majority of this has been
in Huntington disease (HD)



45mg BID exposure
The dose to be tested in ALS

> 1000 patient years



in 981 patients

 Doses ranging from

10 mg $\xrightarrow{\text{to}}$ 112.5 mg

twice a day (BID)







Safe and tolerable



- Including long term safety data (>5 years) in HD population
- Side effect profile comparable to placebo

Similar incidence of side effects at 45 mg BID as placebo

Most common side effects: placebo vs 45 mg BID



Pridopidine 45 mg BID side effect profile is comparable with placebo

Pridopidine is a highly selective Sigma-1 receptor (S1R) activator for the treatment of ALS



Validated target

S1R genetic loss of function mutations cause ALS in humans

Lack of S1R ↑ progression in ALS mouse model



Neuroprotective in animal models

↑ Neuronal survival
↑ Neuron function
↑ Muscle contractility
↓ Muscle atrophy



Human target engagement

Robust and selective S1R binding in the brain and spinal cord



Safe and tolerable


Extensive safety data in >1300 patient years

45 mg BID shows placebo-like safety and tolerability

Compelling evidence supports therapeutic potential of pridopidine in ALS

Backup

Pridopidine is administered orally twice a day



Pridopidine is packed in **small easy to swallow** gelatin capsules